Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,405 across all filing types
Latest filing 2018-03-28 Director's Dealing
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is identified by the 'RNS Number' header and explicitly mentions 'Disclosure under Article 19 of the EU Market Abuse Regulation'. It details 'TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES (PDMRs)' regarding the vesting of shares under a bonus plan for executives (Pascal Soriot and Marc Dunoyer). This type of filing, reporting personal share transactions by directors and executives, directly corresponds to the definition of Director's Dealing (DIRS). Although it is distributed via RNS, the specific content mandates the DIRS classification over the general RNS fallback.
2018-03-28 English
6-K Filing
Regulatory Filings
2018-03-28 English
Director/PDMR Shareholding
Remuneration Information Classification · 99% confidence The document is explicitly marked with an 'RNS Number' and contains an announcement titled 'TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES'. This type of filing details share transactions by directors and executives (insider trades). This directly matches the definition for Director's Dealing (DIRS). Although it mentions the Annual Report for context on performance measures, the primary purpose and format (short regulatory announcement ending with 'END' and RNS footer) classify it as DIRS, which is a specific type of regulatory disclosure, often disseminated via RNS.
2018-03-26 English
6-K Filing
Regulatory Filings
2018-03-26 English
Lokelma approved in the EU
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated March 22, 2018. It announces a significant corporate event: the European Commission granting marketing authorisation for a drug, Lokelma. This type of announcement, which is a material event disclosure disseminated via the Regulatory News Service (RNS) system, fits best under the general 'Regulatory Filings' category, as it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific insider transaction (DIRS). Since it is a general regulatory announcement disseminated through the RNS system, RNS is the most appropriate code.
2018-03-22 English
6-K Filing
Regulatory Filings
2018-03-22 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.